Universität zu Köln

Simões Correa Galendi, Julia ORCID: 0000-0002-4832-7294, Rasch, Hannes ORCID: 0009-0007-1483-1015, Caramori, Carlos Antonio ORCID: 0000-0002-0390-1061, Gaiolla, Rafael Dezen ORCID: 0000-0002-9480-4995, Müller, Dirk ORCID: 0000-0002-5576-0192 and Nogueira, Vania Santos Nunes ORCID: 0000-0001-9316-4167 (2025). Cost-Effectiveness and Value of Information Analyses of Caplacizumab for the Treatment of Thrombotic Thrombocytopenic Purpura in Brazil. Applied Health Economics and Health Policy, 23 (4). pp. 649-660. Springer Nature. ISSN 1175-5652

PDF s40258-025-00968-7.pdf Bereitstellung unter der CC-Lizenz: Creative Commons Attribution Non-commercial No Derivatives. Download (1MB)

Abstract

Objectives: The objective was to evaluate the cost effectiveness of caplacizumab for the treatment of patients with acquired immune thrombocytopenic thrombotic purpura (iTTP) compared to standard of care from the perspective of the Brazilian Unified Health System (SUS). Methods: A decision tree followed by a Markov model with a lifetime horizon was developed. Patients entered the model with an acute iTTP event. All patients were assumed to be admitted to hospital where they either respond to treatment or die. The model offered three health states: remission, relapse or death. Input data were obtained from literature searches with the data on efficacy of caplacizumab based on the HERCULES trial. The incremental cost-effectiveness ratio (ICER) was compared to the willingness-to-pay threshold for rare diseases of Brazilian reais (R$)120,000/quality-adjusted life years (QALYs). In addition to various sensitivity analyses, a value of information (VOI) analysis was conducted. Results In the base case, caplacizumab resulted in 0.70 QALYs gained, and cost R$1,333,601 more, with an ICER of R$1,901,729/QALY. The cost of the caplacizumab vial was the most influential parameter. Probabilistic analysis showed that caplacizumab was not cost effective in any iterations for the threshold of the rare disease. The expected value of perfect information per year is R$0. Conclusion: Although caplacizumab results in incremental QALYs, based on the proposed cost, caplacizumab is not cost effective from the SUS perspective, and VOI results indicate that further research would not be worthwhile.

Item Type:	Article
Creators:	Creators Email ORCID ORCID Put Code Simões Correa Galendi, Julia UNSPECIFIED https://orcid.org/0000-0002-4832-7294 UNSPECIFIED Rasch, Hannes UNSPECIFIED https://orcid.org/0009-0007-1483-1015 UNSPECIFIED Caramori, Carlos Antonio UNSPECIFIED https://orcid.org/0000-0002-0390-1061 UNSPECIFIED Gaiolla, Rafael Dezen UNSPECIFIED https://orcid.org/0000-0002-9480-4995 UNSPECIFIED Müller, Dirk UNSPECIFIED https://orcid.org/0000-0002-5576-0192 UNSPECIFIED Nogueira, Vania Santos Nunes UNSPECIFIED https://orcid.org/0000-0001-9316-4167 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-801037
Identification Number:	10.1007/s40258-025-00968-7
Journal or Publication Title:	Applied Health Economics and Health Policy
Volume:	23
Number:	4
Page Range:	pp. 649-660
Number of Pages:	12
Date:	24 July 2025
Publisher:	Springer Nature
ISSN:	1175-5652
Language:	English
Faculty:	Faculty of Medicine
Divisions:	Faculty of Medicine > Gesundheitsökonomie > Institut für Gesundheitsökonomie und Klinische Epidemiologie
Subjects:	Medical sciences Medicine
['eprint_fieldname_oa_funders' not defined]:	Publikationsfonds UzK
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/80103